Lexicon Pharmaceuticals, Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 6 August 2026: press release. Guidance figures: 1 lowered, 3 kept. The quarter’s numbers.

Read the filing

Key takeaways

• Revenue fell against licensing-led prior year: Total revenues were $0.7 million, all INPEFA net sales. The second quarter of 2025 included $27.6 million of Novo Nordisk licensing revenue, so comparable revenue fell sharply. Source
• Net loss of $31.8 million: The company reported a net loss of $31.8 million, or $0.07 per share, against net income of $3.3 million, or $0.01 per share, a year earlier. Loss from operations was $26.5 million. Source
• SONATA-HCM enrollment completed: The pivotal Phase 3 placebo-controlled study substantially exceeded its 500-patient target. Most enrolled patients have non-obstructive HCM, with a meaningful cohort of obstructive HCM patients. Source
• NDA resubmission now expected Q4 2026: Resubmission is anticipated in the fourth quarter of 2026. The first-quarter document had said the company was on track for resubmission and approval in 2026. Source
• Third Novo milestone possible later this year: Lexicon received $45 million upfront and two $10 million development payments. A third $10 million milestone is eligible as early as later this year, within up to $1 billion in total milestones plus tiered royalties. Source
• Cash and investments $190.6 million: Cash and investments were $190.6 million at June 30, 2026, compared with $125.2 million of cash, investments and restricted cash at December 31, 2025. Source

“Among all the accomplishments, I’m particularly pleased that we have completed enrollment of our SONATA-HCM study on time”

Mike Exton, Ph.D., Lexicon’s chief executive officer and director

Guidance

What changed from last quarter

• Guidance lowered: The expected timing of the ZYNQUISTA NDA resubmission moved from mid-2026, per the first-quarter document, to the fourth quarter of 2026. Source
• New: SONATA-HCM enrollment was completed, which the first-quarter document had expected in mid-2026. Source
• New: Viatris has heart failure approval in Bahrain, in addition to the United Arab Emirates named in the first-quarter document. Source

Quarterly results and revenue

• Revenue fell against licensing-led prior year: Total revenues were $0.7 million, all INPEFA net sales. The second quarter of 2025 included $27.6 million of Novo Nordisk licensing revenue, so comparable revenue fell sharply. Source
• Net loss of $31.8 million: The company reported a net loss of $31.8 million, or $0.07 per share, against net income of $3.3 million, or $0.01 per share, a year earlier. Loss from operations was $26.5 million. Source
• Six-month revenue reflects first-quarter milestone: Six-month total revenues were $21.8 million. The first-quarter $20.0 million development milestone from Novo Nordisk was the main item, and no licensing revenue was recorded in the second quarter.

Cardiometabolic pipeline milestones

• SONATA-HCM enrollment completed: The pivotal Phase 3 placebo-controlled study substantially exceeded its 500-patient target. Most enrolled patients have non-obstructive HCM, with a meaningful cohort of obstructive HCM patients. Source
• Primary endpoint covers full HCM population: The primary endpoint measures symptom improvement across both non-obstructive and obstructive HCM patients. Topline results are expected in the first quarter of 2027. Source
• LX9851 Phase 1 running under Novo Nordisk: Novo Nordisk started a Phase 1 study in March 2026 of single and multiple ascending doses against placebo in overweight or obese people. Completion is expected in the first quarter of 2027. Source
• Pilavapadin pursuing strategic options: Pilavapadin is an investigational once-daily oral AAK1 inhibitor for neuropathic pain. The company is exploring strategic alternatives to maximize its global potential. Source

“With early commercial planning now underway for our late-state pipeline, we are committed to maximizing the value of these opportunities to create long-term shareholder value.”

Scott Coiante, Lexicon’s chief financial officer

Type 1 diabetes filing path

• NDA resubmission now expected Q4 2026: Resubmission is anticipated in the fourth quarter of 2026. The first-quarter document had said the company was on track for resubmission and approval in 2026. Source
• STENO1 study nearing FDA data needs: The third-party funded STENO Diabetes Center study is approaching the patient exposure and safety data the FDA previously identified as adequate for resubmission. Source
• Safety data support resubmission: Management said the safety data received to date from the open-label trial continue to support the resubmission. Source

Partner programs and licensing

• Viatris heart failure approvals in Gulf: Viatris has approval for heart failure in the UAE and Bahrain. It has submitted applications in twelve further markets, including Saudi Arabia, Canada, Australia, Mexico and Singapore. Source
• Viatris decisions expected in 2026: Decisions are anticipated in Australia and Canada, with further submissions in other markets during 2026. Lexicon continues to support Viatris in its ex-U.S. and ex-Europe regulatory and commercial work. Source
• Third Novo milestone possible later this year: Lexicon received $45 million upfront and two $10 million development payments. A third $10 million milestone is eligible as early as later this year, within up to $1 billion in total milestones plus tiered royalties. Source

“Overall, I could not be more confident in how these opportunities are poised to shape the company over the coming months.”

Mike Exton, Ph.D., Lexicon’s chief executive officer and director

Operating costs and expenses

• R&D rose on Phase 3 trial: R&D expense was $17.4 million, against $15.7 million a year earlier. The increase reflects higher external research spending on the SONATA-HCM trial. Source
• SG&A rose on consulting costs: SG&A expenses were $9.8 million, up from $9.4 million, driven by higher professional and consulting costs. Source
• Non-cash stock compensation held steady: Non-cash stock-based compensation was $3.3 million in the second quarter, against $3.2 million a year earlier, and is included in the net loss. Source

Capital, cash and debt

• Cash and investments $190.6 million: Cash and investments were $190.6 million at June 30, 2026, compared with $125.2 million of cash, investments and restricted cash at December 31, 2025. Source
• Hercules loan tranches tied to milestones: The $100 million Hercules facility funded $55 million at closing, which repaid the Oxford Finance loan. The second $20 million tranche depends on clinical, regulatory and financial milestones. Source
• February equity sale proceeds restated: The February 2026 stock and preferred sale is shown as $96.5 million net proceeds in the first-quarter document and $96.2 million in the second-quarter document. Source

Management focus and capital allocation

• Disciplined capital allocation stressed: CFO Scott Coiante said the company remains focused on disciplined, targeted capital allocation while it advances its clinical programs. Source
• Early commercial planning for late-stage assets: Management said early commercial planning is under way for the late-stage pipeline, with the aim of maximizing value for shareholders. Source
• Strategy refinement and sharper focus: CEO Mike Exton said the refined strategy and sharper focus are beginning to bear fruit across the business. Source

Coming up, as management said on 6 August 2026

• SONATA-HCM topline results: Management expects topline results from SONATA-HCM in the first quarter of 2027. Source
• ZYNQUISTA NDA resubmission: NDA resubmission is anticipated in the fourth quarter of 2026, based on current estimated timing of data collection. Source
• Third Novo Nordisk milestone: A third $10 million milestone payment is eligible as early as later this year. Source
• Viatris regulatory decisions in 2026: Viatris anticipates regulatory decisions in Australia and Canada, with submissions in other markets during 2026. Source
• LX9851 Phase 1 completion: Novo Nordisk expects the LX9851 Phase 1 program to be completed in the first quarter of 2027. Source

Figures management reported

Risks management discussed

• Regulatory: NDA resubmission timing depends on data collection in the third-party funded STENO1 study. Source
• Financial: The third $25 million Hercules tranche needs Hercules consent and meets specified timing requirements before it can be drawn. Source

Earlier plans management reported on

• Met: Enrollment was completed on time. The first-quarter document had expected completion in mid-2026. Source
• Not stated: The first-quarter document said the company was on track for resubmission and approval in 2026. The second-quarter document gives resubmission for Q4 2026 and does not restate approval timing.
• Not stated: Management continues to expect topline results in the first quarter of 2027, the same timing given in the first-quarter document. Source

Other quarters

• Q3 FY2026 earnings call
• Q1 FY2026 earnings call
• Q4 FY2025 earnings call
• Q3 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.